MS drug tested in chinese patients shows promise
NCT ID NCT04667949
Summary
This study tested the safety and effectiveness of the drug fingolimod (Gilenya) in Chinese adults and teens with relapsing multiple sclerosis (RMS). About 100 participants took the daily pill for two years while doctors tracked their relapses and side effects. The goal was to see how well the drug controlled the disease and was tolerated in this specific population.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS (RMS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Beijing, Beijing Municipality, 100000, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510623, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510630, China
-
Novartis Investigative Site
Zhengzhou, Henan, 450052, China
-
Novartis Investigative Site
Wuhan, Hubei, 430030, China
-
Novartis Investigative Site
Suzhou, Jiangsu, 215004, China
-
Novartis Investigative Site
Changchun, Jilin, 130021, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Wenzhou, Zhejiang, 325000, China
-
Novartis Investigative Site
Beijing, 065001, China
-
Novartis Investigative Site
Beijing, 100028, China
-
Novartis Investigative Site
Guangzhou, 510260, China
-
Novartis Investigative Site
Shanghai, 200040, China
Conditions
Explore the condition pages connected to this study.